Search hospitals > California > Truckee
Gene Upshaw Memorial Tahoe Forest Cancer Center
Claim this profileTruckee, California 96161
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
128 reported clinical trials
16 medical researchers
Summary
Gene Upshaw Memorial Tahoe Forest Cancer Center is a medical facility located in Truckee, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Gene Upshaw Memorial Tahoe Forest Cancer Center is involved with conducting 128 clinical trials across 270 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, David R. Gandara, Aaron Rosenberg, and Richard J. Bold.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Stomach Cancer
Studies Thyroid Cancer
33 reported clinical trials
70 drugs studied
David R. GandaraUniversity of California Davis Comprehensive Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
13 reported clinical trials
22 drugs studied
Aaron RosenbergUniversity of California Davis Comprehensive Cancer Center2 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
12 reported clinical trials
21 drugs studied
Richard J. BoldGene Upshaw Memorial Tahoe Forest Cancer Center3 years of reported clinical research
Studies Breast Cancer
Studies Thyroid Cancer
12 reported clinical trials
35 drugs studied
Clinical Trials running at Gene Upshaw Memorial Tahoe Forest Cancer Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Breast cancer
Thyroid Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Rectal Cancer
Oropharyngeal Cancer
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Gene Upshaw Memorial Tahoe Forest Cancer Center?
Gene Upshaw Memorial Tahoe Forest Cancer Center is a medical facility located in Truckee, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Gene Upshaw Memorial Tahoe Forest Cancer Center is involved with conducting 128 clinical trials across 270 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, David R. Gandara, Aaron Rosenberg, and Richard J. Bold.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.